Our Mission
Pioneering a New Era of GPCR Drug Discovery.
The Opportunity
Unlocking the full potential of G protein-coupled receptor (GPCR) drug targets creates the opportunity to develop the next generation of impactful new medicines for patients across therapeutic areas
What we do
Powered by our proprietary, industrial-scale Native Complex Platform™, we are discovering new ways to drug GPCRs
Our industrial-scale platform aims to unlock previously difficult-to-drug GPCRs and has led to the discovery, optimization, and development of our pipeline of oral small molecule drug candidates.
GPCRs regulate physiological processes in nearly every organ system of the human body
Pipeline
Septerna is advancing a deep pipeline of oral small molecule GPCR programs in development and discovery
We are advancing a wholly-owned pipeline focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.
About Us
World-class team of drug hunters, GPCR experts, drug developers, and company builders
We are a strong, values-driven organization aimed at advancing cutting-edge science and relentlessly focused on developing a portfolio of oral small molecule GPCR-targeted programs with novel mechanistic approaches for patients with significant unmet needs.
Collaboration powers our community
Press Releases
Latest News
Septerna to Present at TD Cowen 45th Annual Health Care Conference
Septerna Announces Discontinuation of SEP-786 Phase 1 Clinical Trial and Plans to Advance Next-Generation Oral Small Molecule PTH1R Agonist
Septerna Expands Leadership with Appointment of Industry Veteran Gil Labrucherie as Chief Financial Officer
Septerna Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Septerna, Inc. (Nasdaq: SEPN), today reported financial results for the third quarter...